{"id":"W4281633340","doi":"10.1200/jco.2022.40.16_suppl.12100","title":"Interim analysis of a single-center, single-arm, prospective phase 2 study to evaluate the efficacy and safety of benralizumab for alpelisib rash in metastatic PIK3CA-mutant, hormone receptor–positive breast cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Eosinophilic Disorders and Syndromes","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Augmentium Pharma Consulting (Canada)","funders":"National Institutes of Health","keywords":"Medicine; Benralizumab; Rash; Internal medicine; Clinical endpoint; Metastatic breast cancer; Interim analysis; Breast cancer; Oncology; Cancer; Clinical trial; Mepolizumab; Asthma; Eosinophil","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004902915,0.0001869657,0.002663541,0.0004590657,0.00007601055,0.00000871977,0.0002456479,0.00006151241,0.0001917657],"category_scores_gemma":[0.001960458,0.0001237518,0.0005421866,0.0009662022,0.0002577074,0.00007398836,0.0001848247,0.0005402698,2.254031e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004083932,"about_ca_system_score_gemma":0.0006292397,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00013156,"about_ca_topic_score_gemma":0.0003467258,"domain_scores_codex":[0.9947269,0.001230114,0.002941283,0.0003071592,0.0005551038,0.0002394594],"domain_scores_gemma":[0.9941088,0.003065457,0.001702302,0.0002243911,0.0007056347,0.000193403],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"nonrandomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.2406269,0.2565637,0.1850328,0.0001237952,0.02846273,0.0003704772,0.02264909,0.001469923,0.01239725,0.0001326342,0.001526852,0.2506438],"study_design_scores_gemma":[0.09964713,0.2437951,0.6267058,0.0002278677,0.01217981,0.0003634882,0.01446697,0.001066691,0.0001256353,0.0002490566,0.0009390656,0.0002333513],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9897464,0.0006218217,0.0002254421,0.006930125,0.0003069428,0.00180765,0.0002802202,0.000003137819,0.00007828704],"genre_scores_gemma":[0.9986217,0.0001660391,0.0005643607,0.0004637558,0.00007418575,0.00005146385,0.00001070525,0.00001843782,0.00002935734],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.441673,"threshold_uncertainty_score":0.504645,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1139353397638302,"score_gpt":0.4737291701949902,"score_spread":0.35979383043116,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}